Small-cell lung cancer (SCLC) represents about 15% of all lung cancers and is marked by
an exceptionally high proliferative rate, strong predilection for early metastasis and poor …

Drug repositioning is the process of identifying novel therapeutic potentials for existing drugs
and discovering therapies for untreated diseases. Drug repositioning, therefore, plays an …

We have sequenced the genomes of 110 small cell lung cancers (SCLC), one of the
deadliest human cancers. In nearly all the tumours analysed we found bi-allelic inactivation …

Despite recent advances in the use of immunotherapy, only a minority of patients with small
cell lung cancer (SCLC) respond to immune checkpoint blockade (ICB). Here, we show that …

Until now, the Food and Drug Administration (FDA)-approved iron supplement ferumoxytol
and other iron oxide nanoparticles have been used for treating iron deficiency, as contrast …

Radiation therapy is a mainstay of cancer treatment but does not always lead to complete
tumor regression. Here we combine radiotherapy with blockade of the 'don't-eat-me'cell …

This paper provides an overview of recent developments in big data in the context of
biomedical and health informatics. It outlines the key characteristics of big data and how …

Highlights•There is an emerging need for new therapies for rare diseases in a shorter time
frame.•Drug repurposing could arise from serendipitous observations or exploiting side …

Cysteine cathepsin protease activity is frequently dysregulated in the context of neoplastic
transformation. Increased activity and aberrant localization of proteases within the tumour …

Small cell lung cancer (SCLC) is an aggressive disease that accounts for approximately
14% of all lung cancers. In the United States, approximately 31,000 patients are diagnosed …